State Street’s XLV delivers higher dividends and lower fees than IBB, attracting investors seeking stable healthcare exposure.
State Street’s Health Care Select Sector SPDR ETF (XLV) has demonstrated stronger long-term returns compared to the iShares Biotechnology ETF (IBB), driven by its diversified exposure to pharmaceutical giants and lower costs. XLV’s expense ratio stands at 0.08%, significantly below IBB’s 0.44%, while its trailing 12-month dividend payout reached $2.53 per share on a recent price of $158.66.
XLV tracks the Health Care Select Sector Index, holding 59 stocks including Eli Lilly (16.72%), Johnson & Johnson (10.7%), and AbbVie (7.72%). In contrast, IBB focuses on high-growth biotech firms, offering higher volatility but narrower sector exposure. The SPDR fund’s broader diversification appeals to investors prioritizing stability over speculative gains.
The performance gap underscores differing investor preferences within healthcare, with XLV benefiting from steady dividends and cost efficiency. Both funds serve distinct roles in portfolios, balancing risk and growth potential.